These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 33716638)

  • 41. Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model.
    He Q; Li YH; Guo SS; Wang Y; Lin W; Zhang Q; Wang J; Ma CG; Xiao BG
    Eur J Neurosci; 2016 Jan; 43(1):41-52. PubMed ID: 26565388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine Receptor D3 Expression Is Altered in CD4
    Elgueta D; Contreras F; Prado C; Montoya A; Ugalde V; Chovar O; Villagra R; Henríquez C; Abellanas MA; Aymerich MS; Franco R; Pacheco R
    Front Immunol; 2019; 10():981. PubMed ID: 31118938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
    González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
    J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson's Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology.
    Angelopoulou E; Paudel YN; Villa C; Shaikh MF; Piperi C
    Biology (Basel); 2020 Apr; 9(4):. PubMed ID: 32340360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel anti-inflammatory therapy for Parkinson's disease.
    Gao HM; Liu B; Zhang W; Hong JS
    Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease.
    Korkmaz OT; Tunçel N
    Curr Pharm Des; 2018; 24(39):4693-4701. PubMed ID: 30636594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
    Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
    Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
    Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
    Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease.
    Chu Y; Morfini GA; Kordower JH
    J Parkinsons Dis; 2016; 6(1):77-97. PubMed ID: 27003787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.
    Ventorp F; Bay-Richter C; Nagendra AS; Janelidze S; Matsson VS; Lipton J; Nordström U; Westrin Å; Brundin P; Brundin L
    J Parkinsons Dis; 2017; 7(2):263-273. PubMed ID: 28387682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease.
    Pradhan S; Andreasson K
    Exp Neurol; 2013 Mar; 241():148-55. PubMed ID: 23261765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease.
    Tripathy D; Chakraborty J; Mohanakumar KP
    Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling.
    Meng F; Guo Z; Hu Y; Mai W; Zhang Z; Zhang B; Ge Q; Lou H; Guo F; Chen J; Duan S; Gao Z
    Brain; 2019 Mar; 142(3):700-718. PubMed ID: 30689733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The gut microbiome in Parkinson's disease: A culprit or a bystander?
    Keshavarzian A; Engen P; Bonvegna S; Cilia R
    Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models.
    Wang Q; Qian L; Chen SH; Chu CH; Wilson B; Oyarzabal E; Ali S; Robinson B; Rao D; Hong JS
    Brain; 2015 May; 138(Pt 5):1247-62. PubMed ID: 25716193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.